TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Clinical trial NCT00741169 · COMPLETED

Trial details

NCT number: NCT00741169
Sponsor: Tibotec Pharmaceuticals, Ireland
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatitis C HCV Tuberculosis Rifampin Pharmacokinetics

Start date: 2008-06-01
Primary completion: 2008-12-01
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.